> Back to EJC

2016 editions

  • December 2016
    Joao Incio on mechanisms to explain why obesity promotes cancer.
  • November 2016
    Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer.
  • October 2016
    Ruth Muschel on a new target for treatments for colorectal cancer.
  • September 2016
    Freddie Hamdy on the effectiveness of treatments for prostate cancer.
  • August 2016
    Moshe Oren discusses the effects of the microenvironment on cancer cells.
  • July 2016
    Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
  • June 2016
    Key advances in clinical trials.
  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – November 2014

Loading EJC News Focus video

The astonishing efficacy of CAR-T cells

A patient with leukaemia who has exhausted all other treatment options receives a precision treatment and the cancer disappears 'like ice, when it melts'. Is this possible? US Researchers now believe it is. In phase I trials, they modified patients' own T-cells to include a B-cell antibody – the so-called Chimeric Antigen Receptor T-cells (CAR-T cells) – and infused them back into patients. Extremely sick patients went into remission within a week – and the response has lasted for years.

In this month's EJC News Focus, Carl June (University of Pennsylvania) discusses the research with Helen Saul. A key question is whether, or when, this research can be scaled up to become routine in a wider range of cancers.